ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper

71Citations
Citations of this article
143Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.

References Powered by Scopus

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

10543Citations
N/AReaders
Get full text

Anaphylaxis: Guidelines from the European Academy of Allergy and Clinical Immunology

848Citations
N/AReaders
Get full text

World allergy organization anaphylaxis guidance 2020

624Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

168Citations
N/AReaders
Get full text

Advances and highlights in allergic rhinitis

136Citations
N/AReaders
Get full text

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

112Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Klimek, L., Jutel, M., Akdis, C. A., Bousquet, J., Akdis, M., Torres, M. J., … Chivato, T. (2021). ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 76(6), 1624–1628. https://doi.org/10.1111/all.14726

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 34

58%

Researcher 15

25%

Professor / Associate Prof. 7

12%

Lecturer / Post doc 3

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 34

59%

Nursing and Health Professions 12

21%

Social Sciences 7

12%

Pharmacology, Toxicology and Pharmaceut... 5

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 33

Save time finding and organizing research with Mendeley

Sign up for free